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Changes in the composition of glycans added to glycoproteins and glycolipids are characteristic of the change to malignancy. Sialyl-Tn
(STn) is expressed by 25–30% of breast carcinomas but its expression on normal tissue is highly restricted. Sialyl-Tn is an O-linked
disaccharide that can be carried on various glycoproteins. One such glycoprotein MUC1 is expressed by the vast majority of breast
carcinomas. Both STn and MUC1 have been considered as targets for immunotherapy of breast cancer patients. Here we used
different immunogens to target STn in an MUC1 transgenic mouse model of tumour challenge. We show that synthetic STn coupled
to keyhole limpet haemocyanin (Theratope), induced antibodies to STn that recognised the glycan carried on a number of
glycoproteins and in these mice a significant delay in tumour growth was observed. The protection was dependant on STn being
expressed by the tumour and was antibody mediated. Affinity chromatography of the STn-expressing tumour cell line, followed by
mass spectrometry, identified osteopontin as a novel STn-carrying glycoprotein which was highly expressed by the tumours. These
results suggest that if antibodies can be induced to a number of targets expressed by the tumour cells, a humoral response can be
effective in controlling tumour growth.
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Carcinogenesis is often accompanied by over-expression and/or
aberrant glycosylation of various proteins by cancer cells. For
instance, over-expression of MUC1 carrying truncated and
sialylated O-glycans is considered as a common feature of breast
and other carcinomas (Taylor-Papadimitriou et al, 2002). This
aberrant glycosylation can directly generate cancer-associated
antigens in two ways: (1) by exposure of cryptic protein epitopes
that are normally masked by the extended glycosylation, (2) by
changing the composition of the carbohydrate side chains
attached to the protein resulting in, for example, the Thomsen–
Friedenreich (T), Thomsen-nouveau (Tn) antigens and their
sialylated version sialyl-T (ST) and sialyl-Tn (STn). The loss of
polarity of the epithelial cancer cells allows the exposition of these
antigens on the whole surface of the cell making them accessible to
antibodies and cells of the immune system.
The STn antigen consists of a simple disaccharide expressed in
about 30% of breast cancers (Julien and Delannoy, 2003; Miles and
Papazisis, 2003). The importance of this glycan is demonstrated by
the association of its expression with a decreased overall survival
of breast cancer patients (Julien and Delannoy, 2003) and the lack
of response to chemotherapy (Miles et al, 1994). Expression of STn
has been shown to be dependant on the expression of the
sialyltransferase ST6GalNAc I in breast cancer cell lines (Julien
et al, 2001, 2005; Sewell et al, 2006) and totally correlated with
ST6GalNAc I expression in primary breast tumours (Sewell et al,
2006). As the expression of STn is highly restricted in normal
tissues (Julien and Delannoy, 2003), this antigen has been
considered of interest for the development of anticancer vaccine.
A synthetic STn-keyhole limpet haemocyanin (KLH) vaccine
(Theratope), which consists of 3000mol of disaccharide conju-
gated to 1mol of KLH, has been designed by the biotech company
Biomira (now Oncothyreon, Alberta, Canada; Ragupathi et al,
1999). Pre-clinical studies in mice showed that immunisation with
Theratope can induce STn-specific IgG (for review see Miles and
Papazisis, 2003). Moreover, a phase II clinical study in breast
cancer patients showed that potent STn-specific humoral re-
sponses can be induced following immunisation with this
immunogen, which correlated with the overall survival of patients
(Miles and Papazisis, 2003). However, in the follow-up phase III
trial no benefit for Theratope-immunised patients compared to
control groups was shown. It must be noted however that STn
expression was not evaluated as a prerequisite for study entry and
therefore the possibility of a benefit in a subset of patients whose
tumours expressed STn could not be excluded.
The most common glycoprotein that can carry the STn glycan in
breast carcinomas is the membrane-bound mucin known as
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sMUC1. In breast cancer patients, both humoral (Kotera et al, 1994;
von Mensdorff-Pouilly et al, 2000; Snijdewint et al, 2001) and
cellular (Correa et al, 2005) responses to MUC1 have been
documented and a number of clinical studies have been initiated to
investigate the use of MUC1-based immunogens in different
tumour types (Tang et al, 2008). Unglycosylated MUC1 peptides
corresponding to the tandem repeat domain have been used to
vaccinate patients (Tang et al, 2008) and immune responses have
been noted. However, when humoral responses were seen, the
antibodies were unable to recognise glycosylated MUC1, in
contrast to naturally occurring antibodies (von Mensdorff-Pouilly
et al, 2000).
In this study we used a Balb/c mouse model to investigate the
efficacy of using STn-carrying immunogens to inhibit tumour
growth. For this we developed a tumour cell line (E3STn) that
expresses STn and MUC1 by the transfection of MUC1 and
ST6GalNAc I, the sialyltransferase responsible for the formation of
STn, into 410.4 mammary tumour cell line. MUC1 glycopeptides,
MUC1 glycoprotein and STn formulations were used as immuno-
gens in an MUC1 transgenic model before challenging with the
STn-expressing tumour cells. We found that Theratope (KLH-STn)
vaccination induced tumour protection that was dependant on the
expression of STn by the tumour cells and the presence of
antibodies that could recognise a number of STn-carrying
proteins.
MATERIALS AND METHODS
Mice
Balb/c transgenic mice, homozygous for human MUC1 transgene
expression, were described previously (Sorensen et al, 2006).
Balb/c mice deficient for mature B cells and the production of
antibodies due to the expression of mutant mMT alleles (Qin et al,
1998) were a generous gift from Prof Thomas Blankenstein, Max
Delbruck Centre for Molecular Medicine, Berlin. All animal
experiments were performed under Home Office project licence
PPL70/5930 observing UKCCCR guidelines.
Cell lines
Mouse mammary carcinoma cell line E3, which expresses human
MUC1, has been described previously (Smith et al, 1999). Stable
transfection of murine ST6GalNAc I was performed to obtain the
cell line E3-STn by the method described previously (Sewell et al,
2006). Stable transfectants for human ST6GalNAc I have been
previously described for MDA-MB-231 (Julien et al, 2001) and
T47-D (Sewell et al, 2006). MCF-7-STn was generated as described
(Julien et al, 2001, 2005).
MUC1-derived glycopeptides and glycoprotein
MUC1-pep-unglycosylated consisted of 60 amino acids (60mer)
comprising three tandem repeats of MUC1. To obtain MUC1-pep-
Tn, the same peptide was glycosylated in vitro by recombinant
UDP-N-acetylgalactosamine (UDP-GalNAc): polypeptide GalNAc-
transferases as described (Sorensen et al, 2006; Tarp et al, 2007).
MUC1-pep-Tn is fully O-glycosylated with all potential 15 sites for
O-glycosylation carrying a GalNAc. MUC1-pep-STn was obtained
by sialylating MUC1-pep-Tn in vitro by recombinant ST6GalNAc I
(Sorensen et al, 2006). All 15 sites for O-glycosylation were
carrying an STn disaccharide. MUC1-pep-STn was conjugated to
KLH as a carrier molecule before immunisation (Sorensen et al,
2006; Tarp et al, 2007).
Recombinant MUC1-carrying STn was purified from CHO-K1-
expressing ST6GalNAc-1 as described previously (Sewell et al,
2006). The density of O-glycosylation has been previously
investigated and an average of 3.8 of the five potential sites of
O-glycosylation of each tandem repeat was glycosylated
(Sewell et al, 2006).
Theratope immunisation
Three days before the immunisation schedule, mice were given an
intravenous (i.v.) injection of 2.3mg of cyclophosphamide.
Theratope immunogen, provided by Biomira, was diluted in PBS
and mixed with the enhanzyn adjuvant. Enhanzyn consists of
Detox-B, which is an emulsion of monophosphoryl lipid A,
mycobacterial cell wall and lecithin (Holmberg and Sandmaier,
2001). Mice were then subcutaneously (s.c.) injected with 10mgo f
either Theratope with adjuvant or KLH with adjuvant in a total
volume of 200ml three times at three weekly intervals. Three weeks
after the final injection the mice were challenged with 100mlo f
5 10
6 cells per ml E3-STn or E3 tumour cell suspended in PBS by
s.c. injection into the flank.
MUC1-STn immunisation
Three days before the first immunisation, mice were given an i.v.
injection of 2.3mg of cyclophosphamide. Mice were then injected
s.c. with 10mg of MUC1-pep-STn coupled to KLH or with 10mgo f
MUC1-prot-STn mixed with Freund’s adjuvant (Sigma, Poole, UK)
in a total volume of 200ml. Each animal received a total of four
injections at two weekly intervals. Two weeks after the final
injection the mice were challenged with 100mlo f5 10
6 cells per
ml E3-STn or E3 tumour cell suspended in PBS by s.c. injection
into the flank.
ELISA
Microtitre plates were coated with antigen overnight at 41C with
ovine submaxillary mucin (OSM; 200ng per well), MUC1-pep-STn
(50ng per well), MUC1-pep-Tn (50ng per well) or MUC1-pep-
unglycosylated (50ng per well) and the ELISA was performed as
described previously (Tarp et al, 2007). Isotypes of antibodies in
the sera were determined on OSM plates using class-specific
second antibodies.
Tumour monitoring
Tumour development was monitored three times per week by bi-
dimensional measurement using vernier calipers. Tumour volumes
in mm
3 were calculated as (a b
2)/2, where a is the largest
measure and b is the smallest in mm. Mice were killed when
tumours reached 1–1.5cm or if they ulcerated. Tumour-free
survival was analysed using Kaplan–Meier model in SPSS software
(SPSS UK Ltd., Woking, UK). Each animal was considered to be
positive when a measurable tumour (13.5mm
3) was reported.
Statistical significance was assessed using the Breslow test for
which Po0.1 is considered significant.
Immunohistochemical staining of tumour sections
Frozen sections of human primary breast carcinomas, selected for
their expression or lack of expression of STn, were fixed in ice-cold
methanol/acetone (1:1) for 10min. Sections were stained with
mouse serum (diluted 1:400) or with the monoclonal antibody
(mAb) to STn, TKH2 as described (Sorensen et al, 2006).
Formalin-fixed, paraffin-embedded sections or frozen section of
E3-STn tumours fixed in 4% paraformaldehyde in PBS (30min)
were stained with the antibodies detailed in the Results followed by
an biotinylated-anti-mouse IgG (Dako, Ely, UK) diluted 1:200 and
StreptABComplex/HRP (Dako) as previously described (Sorensen
et al, 2006).
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TKH2 was coupled to CNBr-activated Sepharose 4 Fast Flow (GE
Healthcare, Amersham, UK). E3-STn cells were lysed in Tris-HCl
50mM (pH 7.0), NaCl 150mM, Triton X-100 2% (pH 7) for 4h on
ice and spun to remove large cell debris. Total cell lysate (6mg
protein) was then loaded into the column and the column was
washed with 10 column volumes of PBS before elution with 0.1 M
glycine at pH 2.5. The fractions were immediately neutralised and
submitted to SDS–PAGE and western blotted with TKH2.
Electrophoresis and western blotting
Cell pellets (5–30 10
6 cells) were lysed in 50mM Tris-HCl,
150mM NaCl buffer containing 1% Triton X-100. Proteins (100mg)
or recombinant osteopontin (OPN; 1mg; R&D, Abingdon, UK)
were loaded onto 4–12% gradient acrylamide gel, submitted to
SDS–PAGE electrophoresis under reducing conditions and
electro-transferred on nitrocellulose membranes in accordance
with standard procedures.
Membranes were blocked with 1% BSA in TBS and incubated
with primary antibodies: anti-STn TKH2, anti-MUC1 HMFG1,
polyclonal goat IgG anti-OPN or anti-sera from immunised mice in
TBS Tween 20 0.05%, for 1h. After washing, labelled proteins were
revealed using appropriate secondary antibodies conjugated to
alkaline-phosphatase and NBT/X-phosphate revelation reagent
(Roche, Lewes, UK).
Identification of proteins by nano-HPLC-tandem mass
spectrometry
Proteins eluted from anti-STn affinity chromatography were
lyophilised, dissolved in Laemmli buffer and separated by SDS–
PAGE (7.5–10% gradient). The gel was silver-stained and the
bands of interest were cut and de-stained in a solution containing
1.6% sodium thiosulfate and 1% potassium ferrycyanate. After
reduction and alkylation, proteins were submitted to in-gel
trypsin digestion overnight at 371Ci n2 5 m M ammonium
bicarbonate buffer (sequencing grade modified trypsin; Promega,
Charbonnieres, France) and extracted tryptic peptides were
submitted to nano-HPLC-tandem mass spectrometry analysis as
previously described (Gurcel et al, 2008). Nano-HPLC-nanoESI-
MS/MS analyses were performed on an ion trap mass spectrometer
(LCQ Deca XPþ; Thermoelectron, San Jose, CA, USA) equipped
with a nano-electrospray ion source coupled to a nano flow high-
pressure liquid chromatography (HPCL) system (LC Packings
Dionex, Amsterdam, the Netherlands).
Fragment ion spectra were searched against the Swiss-Prot mus
musculus database (SwissProt 55.2, 362782 sequences, 130497792
residues) using the MS/MS ion search Mascot software (Matrix
Science, London, UK). The search parameters were 1.5Da
tolerance for the parent ion mass (1þ,2þ or 3þ charged) and
0.8Da for the MS/MS fragment ions, one missed cleavage allowed,
carbamidomethylcysteine as fixed modification and methionine
oxidation as possible modification. Protein hits were ranking
according to the protein scores derived from ions scores. Only the
proteins with a significant score were considered (435 with Swiss-
Prot database).
Immunoprecipitation
Snap-frozen tumours were crushed using a Mikro-Dismembrator
II (Braun Biotech, Melsungen, Germany). Tumour powders were
dissolved in lysis buffer containing the Complete Mini anti-
protease cocktail (Roche) and incubated for 2h at 41C. Lysates
were homogenised and further incubated for 2h. Total tumour
lysates (0.5mg of proteins) were pre-cleared using 50ml of A/G
proteins agarose-beads (Roche) for 2h and incubated with 2mgo f
anti-OPN antibody for 3h. A/G proteins beads were subsequently
added and incubated overnight. Immunoprecipitated proteins
were washed using TBS 0.05% Tween 20, the eluted from the bead
using elution buffer (0.1 M glycine at pH 2.5) for two incubation of
15min each. All procedures were carried out at 41C using ice-cold
reagents. The precipitates were then submitted to SDS–PAGE and
western blotting as described above.
RESULTS
Immunisation with synthetic STn coupled to KLH
(Theratope) induced a humoral response specific to STn
that was not restricted to MUC1-STn
To investigate the efficacy of STn to induce an immune response,
STn conjugated to KLH in the form of Theratope was used to
vaccinate both wild-type (WT) Balb/c mice and MUC1 transgenic
mice on a Balb/c background. The MUC1 transgenic mice were
selected as a model as in breast cancer MUC1 is the major mucin
that carries STn. When Theratope was used in the clinical setting,
patients were given low-dose cyclophosphamide with the aim of
reducing their T-regulatory cells and so enhancing the immune
response (Miles and Papazisis, 2003). Thus, both strains of mice
received a single i.v. injection of 2.3mg of cyclophosphamide 3
days before vaccination with Theratope or KLH.
After three injections, anti-STn antibodies were detected by
ELISA in all the mice that received Theratope (Figure 1A and B).
The antibodies were mostly IgG1 but IgG2a and IgM were also
observed (Figure 1C). The anti-sera induced by Theratope
immunisation in both WT and MUC1 transgenic mice were able
to react with MUC1-pep-STn (60mer with all 15 O-linked
glycosylation sites carrying STn) but not with MUC1-pep-Tn
(60mer with all 15 sites carrying Tn) or MUC1-pep-unglycosylated
(60mer) (Figure 1D). Furthermore, the anti-sera were found to
react with human primary breast cancers expressing STn but were
unable to react with STn-negative tumours (Figure 2A), even
though they expressed the Tn antigen (data not shown).
The ability of anti-STn sera raised in MUC1 TG mice to react
with various STn-positive proteins was analysed by western
blotting. E3-STn and three STn-positive human breast cancer cell
lines, MCF-7-STn, MDA-MB-231-STn (Julien et al, 2001) and T47-
D-STn (Sewell et al, 2006), were used as a source of STn-positive
proteins. As shown in Figure 2B (left panel), these cell lines
expressed variable amounts of different STn-positive proteins
detected using the TKH2 mAb. MUC1 (middle panel) is present in
E3-STn, MCF-7-STn and T47D-STn but barely detectable in MDA-
MB-231-STn cell lysates. Bands corresponding to MUC1 could be
recognised by TKH2 in E3STn and the epithelial breast cancer cell
lines MCF7-STn and T47-D-STn. Anti-sera from mice immunised
with Theratope were weakly able to detect bands of similar
mobility to MUC1-STn (right panel lanes 3a, 3b and 3c) but
reacted more strongly with other STn proteins expressed in E3-
STn or MDA-MB-231-STn cell line. Although the intensity of the
staining obtained was weaker than seen with TKH2, the detection
of the various STn proteins was found to be qualitatively similar.
Moreover, no staining was observed using the same anti-sera to
blot cell lysates from the parental cell lines not transfected with
ST6GalNAc I and therefore not expressing STn (data not shown).
Vaccination with Theratope induced tumour protection in
Balb/c mice
Balb/c WT mice and MUC1 transgenic Balb/c mice that had been
vaccinated with Theratope or controls, as described above, were
tumour challenged with mammary carcinoma cell line expressing
MUC1 and ST6GalNAc 1 (E3-STn) or E3 that express human
MUC1 without STn. Figure 3A shows that MUC1 transgenic mice
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svaccination with Theratope resulted in a delay in the growth of the
E3-STn tumours compared to the KLH group. Furthermore, the
delay in tumour growth was associated with a significant increase
in tumour-free survival as shown in Figure 3B (P¼0.06 in the
Breslow test in which a P-value of 0.1 is considered significant).
Identical results were obtained in the WT Balb/c mice (data not
shown). To confirm the importance of the STn expression in the
tumour protection, we challenged Theratope-vaccinated mice with
E3 tumour cells not expressing the STn glycan. In this case, no
delay in tumour growth was observed, with the Theratope-
vaccinated mice developing tumours as quickly as the control
group (see Figure 3C) and no difference was found in the tumour-
free survival (data not shown).
The protective effect of Theratope is mediated by
antibodies
To ascertain the role of anti-STn antibodies in the tumour
protection observed, we immunised Balb/c mMT KO mice, which
are deficient in antibody production, with Theratope and tumour
challenge with E3-STn cells as described above. Theratope
increased tumour-free survival in WT Balb/c mice (Breslow test,
P¼0.015; Figure 4A) as described above, but not in mMT mice
(Figure 4B; Breslow test, P¼0.74), demonstrating the essential role
of antibodies in the tumour protection induced by Theratope
immunisation.
Tumours from the mice were stained for STn expression using
the mAb TKH2. Focal expression of STn was seen although all the
E3-STn cells expressed STn in vitro (see Supplementary Figure S1).
Faint but uniform staining was also detected in the extracellular
compartment of all the xenografts tested. All three tumours tested
from the Theratope-immunised mice showed weaker expression of
STn than tumours from the mice given adjuvant and KLH alone
and there appeared to be less cellular staining.
MUC1-STn immunisation induced a humoral response but
did not induce consistent protection from tumour
challenge
We have previously shown that a glycopeptide consisting of three
tandem repeats of MUC1 carrying 15 STn glycans coupled to KLH
can induce high titre antibodies in MUC1 transgenic mice
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Figure 1 Immunisation with Theratope induces anti-STn antibodies. Wild-type (A) or human MUC1 transgenic (MUC1 TG). (B) Balb/c mice were
immunised with Theratope or KLH alone (negative control). Sera were collected pre- and post-immunisation. Presence of anti-STn-specific antibodies was
assessed by ELISA using OSM-coated plate. Each set of bars represents 1:3000 diluted serum from a distinct animal (1 representative for the control group
and 10 for the test group). (C) Isotypes of anti-sera (1:3000 dilution) obtained from MUC1 TG after immunisation with Theratope was determined by
ELISA using OSM-coated plates and IgM-, IgG1- or IgG2a-specific second antibodies. (D) Serial dilution of sera from Balb/c WT (triangle) or Balb/c MUC1
transgenic (circle) immunised with Theratope were analysed by ELISA in wells coated with 50ng of MUC1-pep-STn, MUC1-pep-Tn or MUC1-pep-
unglycosylated. Each curve is representative of three independent sera tested. OD, optical density.
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s(Sorensen et al, 2006; Tarp et al, 2007) thus breaking immune
tolerance in this model. Therefore to investigate if the use of a
single glycoprotein carrying STn could also induce tumour
protection, we selected MUC1-carrying STn as an immunogen.
Balb/c MUC1 transgenic mice were immunised MUC1-pep-STn
coupled to KLH (Sorensen et al, 2006; Tarp et al, 2007) or MUC1-
prot-STn (see Materials and Methods). All the mice vaccinated
with MUC1-pep-STn developed high titre antibodies reactive with
MUC1-STn (Figure 5A). In contrast to the antibodies raised
against Theratope, the antibodies cross-reacted with MUC1-Tn
(Supplementary Figure S2A) and stained primary breast tumours
expressing STn and Tn (data not shown). Only 50% of the mice
vaccinated with MUC1-prot-STn developed antibodies reactive
with MUC1-STn (Figure 5C). These sera did not react with
unglycosylated MUC1 peptide and, unlike the antibodies induces
to MUC1-pep-STn, did not cross-reacted with the MUC1-Tn
glycoform (Supplementary Figure S2B). Antibodies induced to
MUC1-pep-STn and MUC1-prot-STn were mostly of the IgG1
subtype but mice immunised with MUC1-pep-STn also developed
IgG2a-specific antibodies (see Supplementary Figure S3). Using
Cos7 cells transfected with MUC1 and/or ST6GalNAc I, we showed
that anti-sera from immunised mice only reacted with Cos7
expressing both MUC1 and STn (see Supplementary Figure S2C).
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Figure 2 Theratope-induced anti-sera are able recognise STn-expressing
breast carcinomas and a broad range of STn-positive proteins. (A) Sections
of STn-positive (a, c, e) or STn-negative (b, d, f) human breast carcinoma
were stained sera from control KLH-immunised mice (a, b), Theratope-
immunised MUC1 TG mice (c, d) or with TKH2 mAb (e, f) to verify
STn expression. This is representative of three different anti-sera tested.
(B) E3-STn (1a, 2a, 3a), MCF-7-STn (1b, 2b, 3b), T47-D-STn (1c, 2c, 3c)
and MDA-MB-231-STn (1d, 2d, 3d) were subjected to western blot
analysis with TKH2 (STn), HMFG1 (MUC1) or anti-sera from the
Theratope-immunised mice as indicated. The figure is representative of
three sera tested.
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Figure 3 Theratope immunisation provided tumour protection. Balb/c
MUC1 transgenic mice (10) were immunised with three injections
Theratope or with KLH (negative control) and then tumour challenged.
(A) Mice were challenged with the STn-positive cell line E3-STn. Growth
rate was monitored by regular measurement of the tumour. (B) Tumour-
free survival was analysed combining two independent experiments and is
represented with a Kaplan–Meier graph. Statistical significance was
calculated using the Breslow test. (C) Mice were challenged with the
STn-negative cell line E3. The results in A and C are representative of two
independent experiments. Bars¼s.d.
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sMoreover, these sera reacted with only with primary human breast
cancers that expressed MUC1 and STn (data not shown).
The MUC1-pep-STn- or MUC1-prot-STn-vaccinated mice were
tumour challenged with E3-STn cells. Although the initial
experiment using MUC1-pep-STn gave a delay in the growth of
tumours in the vaccinated mice compared to the KLH control, this
was not repeated in two subsequent experiments where no
difference was observed in tumour growth between vaccinated
and control animals (Figure 5B). In addition, when MUC1-prot-
STn was used as the immunogen, no difference was seen in the
growth of vaccinated mice compared to control groups in any
experiment (Figure 5D). Injection of cyclophosphamide 3 days
before MUC1-pep-STn or MUC1-prot-STn vaccination had no
effect on the rate of tumour growth and efficacy of tumour
protection (data not shown).
Thus, 10mg per injection of MUC1-pep-STn or MUC1-prot-STn
could induce humoral responses in MUC1 transgenic mice but at
the concentration and in the model used here this did not result in
consistent protection from tumour challenge.
Identification of glycoproteins carrying STn antigen
Because only anti-sera recognising several STn-carrying proteins
were able to mediate tumour protection in our model, it was of
interest to identify these proteins to understand the effect of
Theratope immunisation. We used TKH2 mAb to isolate STn-
proteins from E3-STn cell lystates by immuno-affinity
chromatography. Fractions were analysed by western blot using
TKH2 mAb (Figure 6A). Sialyl-Tn-positive fractions were pooled,
submitted to further SDS–PAGE and 22 individual silver stained
bands ranging from 50 to 4250kDa were analysed by tandem mass
spectrometry analysis after in gel trypsin digestion. Most of the
candidates identified appeared to be abundant cytosolic contami-
nant proteins (actins, myosin 9, heat shock proteins) (see
Supplementary Table S1). However, one candidate identified from
a 50kDa band, the precursor of OPN, appeared to be of interest.
Osteopontin is an extracellular matrix protein known to be
involved in a number of physiological and pathological events,
such as cell-mediated immune response, inflammation, cell survival
and cancer metastasis (Denhardt et al, 2001). Human OPN has a
cluster of five O-glycosylated threonines located next to an RGD
integrin-binding site domain (Christensen et al, 2005). Three of
these threonines are strictly conserved in mammals and OPN has
been found glycosylated in mouse (Christensen et al, 2007).
Therefore, we analysed the E3-STn tumours developed in the
mice for OPN and STn expression. Immunohistochemistry revealed
the homogeneous presence of both OPN and STn in the tumour
(Figure 6B). Osteopontin was homogenously expressed in the
tumour, similar to MUC1 as detected with HMFG2 or 5E5 antibody
(Figure 6B). To confirm the presence of STn as O-glycan linked to
OPN, we immunoprecipitated OPN from whole tumour lysates and
western blotted with TKH2 mAb (Figure 6C). Recombinant
unglycosylated OPN was also probed with an anti-OPN antibody
as control for the electrophoresis pattern. The blot showed that the
major form enriched from the tumour was a high molecular form of
OPN detected as a smear, indicative of various degrees of post-
translational modification. A small portion of this immunoprecipi-
tated OPN was detected by TKH2, indicating that at least part of the
OPN found in the tumour was bearing STn determinants.
DISCUSSION
Glycosylation is one of the most common forms of post-
translational modifications and is essential for many protein and
cellular functions. In malignant cells, changes in carbohydrates
attached to proteins and lipids are frequently observed, resulting in
the expression of cancer-associated glycans. One such glycan, STn,
is found on 25–30% of breast carcinomas but its expression by
normal tissues is highly restricted, making it an attractive
therapeutic target. However, it is generally thought that for active
immunotherapy to be effective it is necessary to induce effector
CD8þ T cells and as unconjugated glycans cannot induce T-cell
responses, their use as immunogens has been restricted. However,
MUC1-carrying STn has been shown to induce high titre antibodies
in MUC1 transgenic mice (Sorensen et al, 2006; Tarp et al,2 0 0 7 ) .
In this paper we report the use of three different STn-based
immunogens, that are synthetic STn coupled to KLH (Theratope),
MUC1-pep-STn coupled to KLH and MUC1-prot-STn, in a MUC1
transgenic mouse model to induce tumour protection. Despite all
the immunised mice developing a strong humoral response we did
not observe consistent tumour protection when the mice were
vaccinated with MUC1-pep-STn or MUC1-prot-STn. However,
further optimisation of the dose and delivery method may enhance
the efficacy of the glycopeptide and glycoprotein used as
immunogens. In contrast, immunisation with Theratope, thus
making the immunogen independent of a specific peptide back-
bone, did result in a significant delay in tumour development.
Furthermore, this effect was strictly dependant on STn being
present in the tumour cells.
The Theratope-immunised mice developed antibodies that
recognised STn carried on MUC1, but also on several other
proteins expressed by E3-STn cells or other STn-positive cell lines.
Tumour challenge experiments performed in Balb/c mMT mice,
which cannot produce immunoglobulins showed no delay in
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Figure 4 Tumour protection induced by Theratope is mediated by
humoral response. Wild-type Balb/c mice (A) or mice deficient in antibody
secretion (mMT) (B) were immunised with Theratope or KLH (negative
control). Tumour-free survival was analysed combining two independent
experiments including 20 and 24 animals per group for A and B
respectively and is represented with a Kaplan–Meier graph and statistical
significance was calculated using the Breslow test.
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stumour growth after vaccination with Theratope, definitively
proving that the tumour protection was dependant upon anti-
STn antibodies. It can be noted that tumour appearance in mMT
mice is delayed compared to WT mice. This phenomenon has
previously been documented by Shah et al (2005) who showed that
mice genetically lacking B cells were more resistant to tumour by
loss of B-cell inhibition of the anti-tumour T cells.
Antibodies could delay tumour growth by antibody-dependent
cellular cytotoxicity, inhibition of function or a combination of the
two mechanisms, and indeed Theratope induced antibodies of the
IgG2a subtype that mediate ADCC in mice (Matthews et al, 1981;
Herlyn and Koprowski, 1982). However, MUC1-pep-STn also
induced IgG2a antibodies (see Supplementary Figure S3) but no
tumour protection was observed in mice immunised with this
immunogen. To determine if inhibition of function is involved in
the delayed tumour growth reported here, it is first necessary to
identify target glycoproteins. Surprisingly, although cancer cell
lines seem to express a variety of O-glycoproteins carrying STn
epitope, few of these proteins have been identified (Clement et al,
2004; Julien et al, 2006). Using affinity chromatography and mass
spectrometry, we identified OPN as an STn-positive protein that
was expressed by the tumour. This is the first time a secreted
protein of the extracellular matrix has been shown to be modified
by cancer-associated glycosylation.
Osteopontin is expressed in most normal tissues during
remodelling. It functions both as a cell attachment and chemotac-
tic protein, mainly by interacting with integrins through an RGD
domain, and also by interacting with CD44 (Denhardt et al, 2001).
Interestingly, sialylation of OPN has been shown to influence its
binding properties (Shanmugam et al, 1997). Because OPN is
expressed in most primary carcinomas (Brown et al, 1994) it is
thought to have a basic function in tumour progression, and in
breast cancer over-expression of OPN is associated with lymph
node metastasis and poor prognosis (see Tuck et al, 2007 for
review). Proposed mechanisms of action of OPN include induction
of survival, enhanced migration or immune regulation. Thus
antibodies that bind STn carried on OPN produced by the tumour
cells may block the function of this glycoprotein leading to a
delayed tumour growth. Our initial results suggest that further
studies into targeting specific glycoforms of OPN as a potential
therapeutic approach in STn-positive breast cancers is warranted.
The results presented in this study demonstrate that STn glycans
as present in Theratope can effectively produce tumour protection
against STn-expressing cancer cells, which is strictly dependant on
the induction of antibodies reactive with STn. The results also
suggest that targeting STn carried on several proteins rather than
only one is more likely to interfere with various mechanisms
involved in tumour development. Moreover the targeting of
multiple antigens may be advantageous in overcoming the
problem of immunoediting that has been documented in a number
of clinical studies (Dudley et al, 2005; Singh and Paterson, 2007)
and although diminished STn expression could still be found on
tumours from mice vaccinated with Theratope. In the light of our
results, we suggest that anticancer strategies using Th2 immune
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Figure 5 Immunisation of MUC1 TG mice with MUC1-pep-STn or MUC1-prot-STn induces anti MUC1-STn antibodies but does not provide tumour
protection. Balb/c MUC1 transgenic mice (10) were immunised with MUC1-pep-STn (A), MUC1-prot-STn (C), KLH alone (control A) or PBS (control C).
Sera were collected pre- and post-immunisation, and the presence of anti-STn-specific antibodies was assessed by ELISA using a MUC1-pep-STn
glycopeptide-coated plate. Each set of bars represents 1:1000 diluted serum from a distinct animal (1 representative for the control group and 10 for the
test group). OD, optical density. (B and D) After a series of four injections, mice were submitted to a tumour challenge, by injecting E3-STn cells
subcutaneously. Growth rate was monitored by regular measurement of the tumour. Bars¼s.d..
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sresponse have been underestimated and warrant further investiga-
tions. Moreover, the expression of STn on the tumour is crucial for
an effect on tumour growth. In the phase III clinical trial with
Theratope where significant therapeutic benefit was not observed,
the STn expression of the tumours was not documented. Thus it is
possible that the subgroup of patients with STn-expressing
tumours may have benefited but the effect was obscured by the
enrolment of patients whose tumours did not express the glycan.
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